DalsnaFinance

Viatris $VTRS

Health Care · Pharmaceuticals · NYSE/NASDAQ

S&P 500 Russell 1000 Pennsylvania
Create a scorecard
$18.22
+0.78 (+4.47%)
As of Oct 15, 2026, 11:12 PM EDT
Price history
Loading chart…

Viatris (VTRS) is trading up at $18.22 (+4.47%) on NYSE/NASDAQ, as of the latest quote. It is a S&P 500 constituent in the Health Care sector.

Viatris revenue & net income history (FY2018–FY2025)

RevenueNet incomeNet margin (right axis, %)
$17.9B$7.19B−$3.51BFY2018 revenue: $11.4BFY2018 net income: $352.5M · Net margin 3.1%'18FY2019 revenue: $11.5BFY2019 net income: $16.8M · Net margin 0.1%'19FY2020 revenue: $11.9BFY2020 net income: −$669.9M · Net margin −5.6%'20FY2021 revenue: $17.9BFY2021 net income: −$1.27B · Net margin −7.1%'21FY2022 revenue: $16.3BFY2022 net income: $2.08B · Net margin 12.8%'22FY2023 revenue: $15.4BFY2023 net income: $54.7M · Net margin 0.4%'23FY2024 revenue: $14.7BFY2024 net income: −$634.2M · Net margin −4.3%'24FY2025 revenue: $14.3BFY2025 net income: −$3.51B · Net margin −24.6%'25−5.9%0%10%20%30%FY2018 net margin: 3.1%FY2019 net margin: 0.1%FY2020 net margin: −5.6%FY2021 net margin: −7.1% (off the scale, which stops at −5.9%)FY2022 net margin: 12.8%FY2023 net margin: 0.4%FY2024 net margin: −4.3%FY2025 net margin: −24.6% (off the scale, which stops at −5.9%)
Viatris annual financial statements
FY2018Dec 2018FY2019Dec 2019FY2020Dec 2020FY2021Dec 2021FY2022Dec 2022FY2023Dec 2023FY2024Dec 2024FY2025Dec 2025
Income statement
Revenue$11.4B$11.5B$11.9B$17.9B$16.3B$15.4B$14.7B$14.3B
Growth (year over year)—+0.6%+3.9%+49.7%−9.1%−5.1%−4.5%−3.0%
Gross profit$4.00B$3.90B$3.80B$5.58B$6.50B$6.44B$5.62B$5.01B
Gross margin35.0%33.9%31.8%31.2%40.0%41.7%38.2%35.1%
Operating income$905.6M$715.5M−$210.8M−$34.0M$1.61B$766.2M$10.1M−$2.66B
Operating margin7.9%6.2%−1.8%−0.2%9.9%5.0%0.1%−18.6%
Net income$352.5M$16.8M−$669.9M−$1.27B$2.08B$54.7M−$634.2M−$3.51B
Net margin3.1%0.1%−5.6%−7.1%12.8%0.4%−4.3%−24.6%
EPS (diluted)$0.68$0.03−$1.11−$1.05$1.71$0.05−$0.53−$3.00
Balance sheet
Cash and equivalents$388.1M$475.6M$844.4M$701.2M$1.26B$991.9M$734.8M$1.32B
Total assets—$31.3B$61.6B$54.8B$50.0B$47.7B$41.5B$37.2B
Total liabilities—$19.4B$38.6B$34.4B$28.9B$27.2B$22.9B$22.5B
Long-term debt—$11.2B$22.4B$19.7B$18.0B$16.2B$14.0B$12.5B
Shareholders' equity$12.2B$0$23.0B$20.5B$21.1B$20.5B$18.6B$14.7B
Cash flow
Operating cash flow$2.34B$1.80B$1.23B$3.02B$3.00B$2.90B$2.30B$2.32B
Capital expenditure$252.1M$213.2M$243.0M$457.2M$406.0M$377.0M$326.0M$378.8M
Free cash flow$2.09B$1.59B$988.8M$2.56B$2.59B$2.52B$1.98B$1.94B
Share buybacks$432.0M$0$0$0$0$250.0M$250.0M$500.5M

From Viatris's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

About Viatris

Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania. The corporation was formed through the merger of Mylan and Upjohn, a legacy division of Pfizer, on November 16, 2020.

Source: Wikipedia — Viatris

Headquarters
Canonsburg, Pennsylvania From SEC filings, Oct 2026

Recent News (19)

More Health Care stocks

Browse all companies →